Podcasts about Illumina

After losing both her sister and a close friend to cancer in the same year, Carissa Rollins knew she couldn't stay where she was. As CIO of UnitedHealthcare, she had scale and power, but not proximity to the technology that might have changed those outcomes. So when the call came from Illumina, a company pioneering genomic sequencing, she listened. And then she leapt. In this episode of Inspiring Women with Laurie McGraw, Carissa shares how grief reshaped her career and how purpose—not title—has always been her compass. She talks candidly about what it means to walk away from the “biggest job of your life” to chase deeper impact, and how she's now using her insider knowledge of the payer system to open doors for patients who would otherwise be left out of the genomic revolution. Carissa also reflects on the turning points that built her leadership style—from writing a three-page letter to fight for a promotion, to insisting on coaching even when her boss said she didn't need it. She's quick to credit the mentors who pulled her forward—but equally passionate about pulling others up behind her. “Why are you sitting in the back?” she recalls asking one young woman. “Your voice is important.” Now at Illumina, she's helping her teams think critically about how AI can reduce burnout—not by cutting jobs, but by removing outdated, burdensome processes and freeing people to do more meaningful work. It's a nuanced, systems-based view that resists the hype and centers on impact. You'll also hear Carissa speak on: Why she sees restlessness as a sign it's time to grow The alarming drop in women in tech—and what we can do about it How the Grand Canyon Conservancy helps her stay grounded (and where she thinks tech could help the parks) What it really takes to make space at the table—and why women can't afford to close the door behind them This conversation is full of hard-earned wisdom, honest reflections, and a fierce belief in using every ounce of power to move others forward. Chapters 03:52 Overcoming Restlessness & Seeking New Challenges 10:05 Impact, Market Access & Personal Fulfillment 14:59 AI's Role in Operations & Efficiency 15:53 Inspiring Young Women in Technology 17:38 Challenges & Setbacks for Women in Tech 19:52 Empowering Advice for Future Leaders Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Carissa Rollins on LinkedIn About Illumina Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify This episode of Inspiring Women with Laurie McGraw was recorded at the WBL Summit, a leadership, networking, and professional development conference for WBL members that takes place each spring. WBL is a network of 1500+ senior executive women in healthcare who convene to share ideas, make valuable connections, and solve business challenges. WBL's mission is to connect and support our members in advancing their careers and impact on our industry.

In this week's Digital Health Roundup, Medtech Insight's Marion Webb highlights her interview with Gary Guthart, CEO of Intuitive Surgical about the new da Vinci 5 surgical robot and the future of robotics in surgery. Brian Bossetta talks about the recently FDA-cleared patient monitoring system that sends vital signs directly to clinician staff. Elizabeth Orr discusses an FDA warning letter to Exer Labs and Shubham Singh discusses Roche's new NGS Prototype, expected to challenge Illumina.

Sarah Burge, Director of Clinical Integration at CRUK Cambridge Centre, Illumina's Alison Shelley, Natasha Robertson, Corporate Partnerships Manager, Addenbrooke's Charitable Trust (ACT) tell Julian about their involvement in the Cambridge […]

PALESTRINA: Misa “Aeterna Christi Munera” a 4 vv (21.25). Coro de la Abadía de Westminster. Dir.: J. O’Donnell. Laudate dominum onmes gentes (2.40). Terra tremuit (2.10). Ascendit deus (1.58). Incipit oratio (7.40). Illumina oculos meos (2.46). Ego sum panis vivus (2.57). Coro de la Catedral de Regensburg. Dir.: T. Schrems.Escuchar audio

ROMA (ITALPRESS) - ROMA (ITALPRESS) - Promuovere un'alimentazione sana, equilibrata e soprattutto colorata. È l'obiettivo di "Attiviamoci con l'Arcobaleno in tavola", il nuovo contest di Sport e Salute che si rivolge agli oltre 2 milioni di studenti delle 12mila scuole primarie e secondarie di primo grado di tutta Italia, già coinvolte dal progetto "Scuola Attiva". In collaborazione conWarner Music Italia, Sport e Salute porta l'energia della musica e dello sport a un nuovo livello, utilizzando linguaggi universalicapaci di coinvolgere i ragazzi in modo dinamico e innovativo. Nasce così il brano "L'Arcobaleno in tavola", presentato aMilano nella sede di Warner Music Italia dall'Amministratore delegato di Sport e Salute, Diego Nepi Molineris, dal VP Finance &CFO di Warner, Raffaele Razzini, e dall'icona del volley italiano Andrea Lucchetta, membro del team "Illumina" di Sport e Salute etestimonial del contest. gm/gtr(Fonre video: Sport e Salute)

ROMA (ITALPRESS) - ROMA (ITALPRESS) - Promuovere un'alimentazione sana, equilibrata e soprattutto colorata. È l'obiettivo di "Attiviamoci con l'Arcobaleno in tavola", il nuovo contest di Sport e Salute che si rivolge agli oltre 2 milioni di studenti delle 12mila scuole primarie e secondarie di primo grado di tutta Italia, già coinvolte dal progetto "Scuola Attiva". In collaborazione conWarner Music Italia, Sport e Salute porta l'energia della musica e dello sport a un nuovo livello, utilizzando linguaggi universalicapaci di coinvolgere i ragazzi in modo dinamico e innovativo. Nasce così il brano "L'Arcobaleno in tavola", presentato aMilano nella sede di Warner Music Italia dall'Amministratore delegato di Sport e Salute, Diego Nepi Molineris, dal VP Finance &CFO di Warner, Raffaele Razzini, e dall'icona del volley italiano Andrea Lucchetta, membro del team "Illumina" di Sport e Salute etestimonial del contest. gm/gtr(Fonre video: Sport e Salute)

In honor of Rare Disease Day, we discuss news from Healx, a clinical-stage biotech, which has dosed the first patient in a Phase II trial of its new drug for neurofibromatosis type 1. In the world of AI, the Arc Institute in collaboration with Nvidia has dropped Evo 2, the “largest publicly accessible AI model for biology to date,” for designing genomes. Additionally, new work from Nobel Laureate, David Baker, uses AI to generate enzymes from scratch. We also dig into the big announcements from Illumina and Roche that got the community buzzing ahead of this year's AGBT meeting. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Healx Candidate, SpringWorks Therapy Expand NF1 Treatment OptionsBy Alex Philippidis, GEN Edge, February 25, 2025 Arc Institute's AI Model Evo 2 Designs the Genetic Code Across All Domains of Life By Fay Lin, PhD, GEN Edge, February 19, 2025 AI-Driven Protein Design Produces Enzyme that Mimics Natural Hydrolase Activity By Corinna Singleman, PhD, GEN, February 13, 2025 Illumina Unveils Spatial Technology Days Before AGBT Meeting By Julianna LeMieux, PhD, GEN, February 19, 2025 StockWatch: Illumina Tumbles on Q4 Results, China Retaliation By Alex Philippidis, GEN Edge, February 8, 2025 Roche Announces SBX Technology, Creates Sequencing Buzz By Julianna LeMieux, PhD, GEN, February 21, 2025 StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks By Alex Philippidis, GEN Edge, February 17, 2025 Hosted on Acast. See acast.com/privacy for more information.

Xung đột thương mại Mỹ - Trung lần thứ hai thay đổi theo từng ngày. Bắc Kinh sử dụng lại đúng chiến lược của Washington trong các đòn đáp trả. Trong hơn 20 ngày đầu cuộc chiến, đôi bên trong thế « vừa đánh vừa nghe » : đó là chiến thuật câu giờ để chuẩn bị cho một cuộc giao tranh dài hơi và khốc liệt hơn ? Trung Quốc có không ít vũ khí để lao vào một cuộc đọ sức mà Nhà Trắng đã khơi mào. Trung Quốc là mục tiêu hàng đầu mà tổng thống Donald Trump nhắm tới trong các cuộc chiến thương mại do Nhà Trắng mở ra. Ở màn 1 khi loan báo tăng thuế nhập khẩu nhắm vào Trung Quốc, Canada và Mêhicô tổng thống Mỹ đã nhẹ tay hơn với Trung Quốc. Để rồi Washington đến giờ chót đã « tạm tha » cho hai nước láng giềng sát cạnh tại Bắc Mỹ nhưng với Trung Quốc thì không. Từ ngày 04/02/2024 hàng made in China nhập khẩn vào Mỹ bị đánh thuế thêm 10 %. Lập tức Bắc Kinh tuyên bố đáp trả « một cách tương xứng ». Dầu hỏa và khí đốt của Mỹ xuất khẩu sang Hoa Lục bị áp thuế thêm 10 và 15 %. Nhưng thuế hải quan không là công cụ duy nhất chủ tịch Tập Cận Bình có trong tay để đối phó với « trận bão Donald Trump ».  Những diễn biến bất ngờ trong cuộc đấuMột điểm đáng chú ý khác, là trong suốt thời gian gần ba tuần qua, có nhiều tin trái ngược về một cuộc điện đàm giữa lãnh đạo hai siêu cường kinh tế thế giới này. Một quan chức của Nhà Trắng loan báo các ông Trump và Tập dự trù một cuộc họp trong ngày 04/02/2025 để rồi lập tức sau đó tổng thống Hoa Kỳ tuyên bố « ông không vội » trao đổi với phía Bắc Kinh. Nhưng khi Bắc Kinh đánh thuế hàng của Mỹ, thì Donald Trump cho biết ông đã « trao đổi » với ông Tập Cận Bình. Không thấy Trung Quốc đề cập đến một cuộc trao đổi ở cấp cao như vậy.Chỉ biết rằng hôm 09/02/2025 Bắc Kinh loan báo « đánh thuế vào 14 tỷ đô la hàng Mỹ xuất khẩu sang Hoa Lục » và biện pháp này có hiệu lực ngay vài giờ sau đó, tức là không để cho đối phương có nhiều thời gian « kịp trở tay ». Nhìn kỹ vào danh sách trừng phạt, 2 tờ báo tài chính Financial Times (Anh) và Nikkei Asia (Nhật Bản) cùng ghi nhận Trung Quốc mạnh tay hơn một chút so với những biện pháp đã được bộ Thương Mại Trung Quốc thông báo trước đó.Như đã được báo trước, than đá và khí hóa lỏng của Mỹ xuất khẩu sang Trung Quốc bị tăng thuế 15 %. Riêng dầu thô của Hoa Kỳ, các thiết bị nông nghiệp, xe chở hàng và ô tô có lượng phát thải lớn bị tăng thuế thêm 10%. Ngoài dự báo, Trung Quốc không chỉ sử dụng biện pháp thuế quan để đáp trả, mà còn « kiểm soát các hoạt động xuất khẩu liên quan đến 25 khoáng sản và công nghệ sang » của Trung Quốc sang Hoa Kỳ. Trung Quốc đồng thời mở rộng thêm danh sách các tập đoàn của Hoa Kỳ bị điều tra với lý do đó những công ty « không đáng tin cậy ». Google, hai tập đoàn may mặc Calvin Klein, Tommy Hilfiger và công ty Illumina trong lĩnh vực công nghệ sinh học bị Trung Quốc điều tra.Washington và Bắc Kinh cùng dùng đòn « giơ cao đánh khẽ » Tờ Financial lưu ý độc giả trong các thông cáo chính thức, Bắc Kinh khéo léo nhắc nhở Nhà Trắng « với 5 loại đất hiếm cần thiết cho công nghiệp sản xuất vũ khí, pin mặt trời, bình điện cho xe ô tô điện của Mỹ, Trung Quốc đang làm chủ chuỗi cung ứng ». Trung Quốc sản xuất 60 % kim loại hiếm sử dụng trên thế giới và 90 % đất hiếm được sàng lọc và chế biến để có thể được đưa vào các nhà máy ở bất kỳ nơi nào trên thế giới đều phải qua tay Trung Quốc.Nhà báo Pierre Haski từng là thông tín viên của nhật báo Libération tại Bắc Kinh và hiện đặc trách mục địa chính trị trên đài phát thanh France Inter, phân tích về chiến lược « giơ cao đánh khẽ » của cả đôi bên : «  Chúng ta chớ bị đánh lừa : trong trận chiến thương mại lần này, Mỹ nhẹ tay với Trung Quốc hơn là với hai nước bạn là Canada và Mêhicô khi tăng thuế nhập khẩu. Trước đây ông Trump từng tuyên bố sẽ đánh thuế 60 %, thậm chí là 100 % hàng Trung Quốc bán sang Hoa Kỳ, để rồi hiện tại chỉ tăng thêm 10 % mà thôi. Donald Trump muốn chứng minh rằng ông nói là làm và có thể giáng mạnh vào kinh tế của đối phương. Về phía Trung Quốc cũng vậy : Bắc Kinh đã phản ứng một cách chừng mực. Hiện tại Trung Quốc vẫn bán đất hiếm cho Mỹ, tức là tránh đụng vào một tử huyệt của nền công nghiệp Hoa Kỳ. Nhưng đòn này nhằm nhắc nhở Washington rằng, Bắc Kinh có nhiều là chủ bài trong tay. Cùng lúc Trung Quốc loan báo đánh thuế 10-15 % nhắm vào dầu và khí đốt của Mỹ, nhưng Hoa Kỳ không là nguồn cung cấp chính của Trung Quốc và như vậy không phương hại gì nhiều đến các nhà sản xuất ở Mỹ mà bản thân tăng trưởng của Trung Quốc cũng không bị thiệt hại. Về thứ ba là Bắc Kinh mở lại điều tra nhắm vào một vài tập đoàn Mỹ nhưng đó mới chỉ là một vài tín hiệu Trung Quốc ngầm nhắn gửi đến Washington ».Về thực chất đôi bên cùng chỉ đưa ra những biện pháp trả đũa mang tính tượng trưng nhưng tránh gây tổn thất quá lớn cho đối phương và cho chính mình, thí dụ như Trung Quốc tránh đánh vào nông phẩm của Mỹ vì đây là nguồn cung cấp 20 % đậu tương cho Hoa Lục (theo Nikkei Asia). Nhà báo Anthony Bellange, đài France Inter, cho rằng cả Washington lẫn Bắc Kinh cùng để ngỏ khả năng đối thoại.«  Phản ứng của Trung Quốc rất chừng mực và thông minh : Washington cần hiểu rằng nếu cần Bắc Kinh sẵn sàng tấn vào những tử huyệt của đối thủ. Động đến Google, một tập đoàn mà chỉ có 1 % doanh thu được thực hiện ở Hoa Lục, nhưng qua đó Trung Quốc cho thấy khi cần, họ sẵn sàng trừng phạt các tập đoàn công nghệ cao của Mỹ. Trong số các tập đoàn đó thì có hãng xe Tesla của Elon Musk. Một thí dụ khác: Trung Quốc tăng thuế nhập khẩu đánh vào dầu và khí đốt của Mỹ để Washington hiểu rằng Bắc Kinh sẵn sàng ngừng nhập khẩu lương thực, thực phẩm của Hoa Kỳ và Bắc Kinh biết rõ đây là một chủ đề nhậy cảm đối với Donald Trump do các nông dân Mỹ là thành phần cử tri ủng hộ ông ». Trung Quốc còn nắm giữ nhiều vũ khí lợi hại Song trong cách đáp trả Washington, Bắc Kinh khéo léo cho thấy Trung Quốc còn nhiều vũ khí trong tay. Nếu như phía Mỹ có thể mạnh tay hơn nhắm vào những công nghệ mũi nhọn mà Trung Quốc đang cần, thì ông Tập Cận Bình cũng có thể khởi động lá chủ bài « kim loại hiếm ». Hơn thế nữa Trung Quốc còn là một chủ nợ của Hoa Kỳ. Theo một nghiên cứu của ngân hàng Pháp Crédit Agricole, tính đến cuối tháng 4/2024 tổng nợ công của nước Mỹ lên tới 34.700 tỷ đô la, Riêng Trung Quốc hiện đang làm chủ 770 tỷ đô la công trái phiếu của Hoa Kỳ, số tiền này tương đương với gần 10 % nợ của Mỹ trong tay các chủ nợ nước ngoài. Pierre Haski nhắc lại thuế hải quan chỉ là một trong số nhiều vũ khí ông Tập Cận Bình có thể huy động nhưng chưa chắc đã là phương tiện nguy hiểm nhất.« Trung Quốc có nhiều cách để trả đũa Hoa Kỳ. Bắc Kinh nắm giữ công trái phiếu của Mỹ và đây được ví như một quả bom nguyên tử, dù vậy biện pháp này chỉ là một dạng vũ khí răn đe vì sử dụng vũ khí này thì Trung Quốc sẽ đánh sập hệ thống tài chính toàn cầu mà Trung Quốc sẽ là một trong những nạn nhân đầu tiên. Phương cách thứ hai là Bắc Kinh có thể ngừng xuất khẩu đất hiếm sang Mỹ. Chúng ta biết trên thị trường này Trung Quốc nắm giữ gần như thế độc quyền mà Mỹ thì cần đất hiếm để phát triển công nghệ tiên tiến. Chính vì thế mà tổng thống Trump có ý định nhòm ngó đến đất hiếm của Ukraina ».Đôi bên cùng biết nhau khá rõ Cả Washington lẫn Bắc Kinh mỗi bên đều biết khá rõ đối thủ đang đứng trước mặt mình. Nhóm cộng sự của Donald Trump tỏ ra quyết liệt vì biết rằng xuất khẩu là một trong những động lực tăng trưởng chính của Trung Quốc. Hiện tại đối thủ của nước Mỹ đang khó nhọc để giữ được mục tiêu tăng trưởng 5 %.Ở góc đài bên kia, ông Tập Cận Bình thừa hiểu tổng thống Mỹ đang chật vật kềm hãm lạm phát. « Phạt » hàng rẻ hay nhôm thép của Trung Quốc đẩy chỉ giá tiêu dùng ở Hoa Kỳ lên cao và đó là điều mà Nhà Trắng khó giải thích được với thành phần cử tri đã bầu cho ông Trump. Dù vậy, tổng thống Mỹ thứ 47 luôn cần « ghi những bàn thắng trong công luận » và đó là một lợi thế để Trung Quốc mặc cả với chính quyền Trump. Pierre Haski nhắc lại trận chiến thương mại lần thứ nhất giữa hai cường quốc kinh tế trên thế giới hồi 2019-2020 :« Cần nhắc lại là trong chiến tranh thương mại lần thứ nhất với Trung Quốc hồi 2019, một cuộc chiến mà chính Hoa Kỳ đã gây nên trong nhiệm kỳ đầu của tổng thống Donald Trump, màn một là Nhà Trắng nhắm vào giám đốc tài chính của tập đoàn trang thiết bị viễn thông Hoa Vi cuối 2018. Đến cuối năm 2019 thì ông Trump ký hiệp định đình chiến với Bắc Kinh : Washington ngừng đánh thuế nhập khẩu vào hàng Trung Quốc. Đổi lại, Bắc Kinh cam kết mua thêm 100 tỷ đô la nông phẩm của Hoa Kỳ để thu hẹp xuất siêu với Mỹ. Chúng ta biết là kế hoạch này không được thực hiện vì những tác động của đại dịch Covid gây nên. Tất cả đã dừng lại ở đó, nhưng Trump vẫn cho rằng ông đã thành công và đã đạt được thỏa thuận với đối phương ».Kinh tế trưởng đặc trách khu vực châu Á thuộc ngân hàng HSBC thẩm định : Mỹ tăng thêm 10 % thuế nhập khẩu, Trung Quốc đủ sức « chịu đựng ». Theo nghiên cứu của Nikkei Asia, nếu chiến tranh thương mại Mỹ-Trung dừng lại ở mức thuế 10 %, GDP của Trung Quốc bị giảm đi mất 0,1 điểm, (tức là mục tiêu tăng trưởng của Bắc Kinh hiện là 5 % trong năm 2025 sẽ bị đẩy xuống còn 4,9 %).Nguy hiểm ở đây là biện pháp trừng phạt đó « mới chỉ là khúc dạo đầu », là « màn đầu tiên » như chính tổng thống Trump đã tuyên bố. Tuy nhiên, tính đến ngày 10/02/2025 chỉ số chứng khoán trên thế giới, nhất là ở Hoa Kỳ và Trung Quốc, Hồng Kông có mất giá đôi chút trong một, hai phiên giao dịch để rồi đã nhanh chóng khởi sắc trở lại. Đó là dấu hiệu các nhà đầu tư tin vào những tính toán thực tiễn của cả Washington lẫn Bắc Kinh. Nhưng ở « hiệp đầu » Mỹ và Trung Quốc cùng trong thế « dàn binh bố trận ».Trước ngày nhậm chức, Donald Trump đã có một cuộc điện đàm với Tập Cận Bình. Nhà Trắng đang gây hỏa mù về một cuộc trao đổi thứ nhì giữa tổng thống Mỹ và chủ tịch Trung Quốc. Một số nguồn tin thông thạo được các báo tài chính Anh Mỹ trích dẫn cho rằng « yếu tố Deepseek » gây bất ngờ trong thế giới công nghệ cao là nguyên nhân « làm trật đường rày » chiến lược của Hoa Kỳ trong cuộc đọ sức với Trung Quốc. Theo ngân hàng Barclays chẳng hạn, Trump và cánh tay mặt của ông Elon Musk khó có thể tỏ ra hòa hoãn với Bắc Kinh ».Về phía Trung Quốc, bộ Ngoại Giao nước này chỉ nhắc tới nguyên tắc chung chung là « đối thoại trên cơ sở bình đẳng và tôn trọng lẫn nhau ». Bắc Kinh không để lộ những nước cờ trước khi lao vào cuộc song đấu với Washington. Các chuyên gia của ngân hàng Anh Barclays chờ đợi, Trung Quốc sẽ có một số cử chỉ hòa hoãn ra vẻ nhượng bộ Hoa Kỳ chẳng hạn như là đồng ý bán lại mạng xã hội TikTok một chi nhánh của tập đoàn ByteDance cho một hãng Mỹ nào đó, giả vờ mở cửa thị trường Trung Quốc với các doanh nhân Trung Quốc và khuyến khích các doanh nghiệp quốc gia cộng sản này đầu tư thêm vào « thị trường tự do » ở Hoa Kỳ…Trái lại một số nhà quan sát khác, như Michael Hirson thuộc văn phòng tư vấn 22VResearch, trụ sở tại New York, thì cho rằng, còn quá sớm để dám khẳng định Mỹ và Trung Quốc đã bước vào đàm phán.Theo chuyên gia này, Bắc Kinh đang « chờ đợi Nhà Trắng có chính sách thương mại rõ ràng và trên cơ sở đó ông Tập Cận Bình mới bật đèn xanh cho các tiến trình thương lượng ». Dù vậy trong cuộc chiến thương mại, Trung Quốc và Hoa Kỳ có một lá chủ bài quan trọng cho phép đôi bên tránh được « kịch bản xấu nhất ». Đó là nhà máy lắp ráp ô tô điện khổng lồ của Tesla tại Thượng Hải mà chủ nhân là Elon Musk, cánh tay mặt của tổng thống Trump. Musk hiện được cho là nhân vật được lãnh đạo ở Nhà Trắng lắng nghe nhất hiện tại.Cho đến nay chủ tich Trung Quốc, Tập Cận Bình chỉ mới đích thân tiếp hai chủ doanh nghiệp Mỹ. Người thứ nhất là chủ tịch tổng giám đốc Apple Tim Cook và người thứ hai là ông chủ Tesla, người đang tham gia nội các Donald Trump.

Will the senior housing market boom continue going forward? Investors may think with the population getting older that investing in senior housing could be a great investment going forward. They could be right as the oldest boomers turn 80 at the end of this year. What's even more amazing is that the US population of 80-year-olds and older will hit 18.8 million in the next five years, that is a 27% increase from today. Senior housing hit a brick wall when the pandemic hit in 2020 and with the high infection rates, loss of life, and social distancing restrictions the demand fell drastically for senior housing. Both the high cost of labor and the shortage of it did not help either. It is estimated in five years they will need 560,000 new units to meet the expected demand. However, due to the high cost of development and the concern that about half of the seniors won't be able to afford private senior housing costs, it's estimated that only about 191,000 units will be added. The good news is more than 40% of seniors could afford senior housing on their income alone, which increased from 30% eight years ago. Unfortunately, those who can afford senior housing would rather not use it and prefer to age at home. Developers are willing to risk their capital on the higher end of the wealthiest seniors building luxury senior housing with fine dining, spas and movie theaters. One high end luxury senior housing project is expected to break ground this year at Rancho Santa Fe in San Diego with 172 units available. I think this sector for investing at this point is worth watching, but I don't think I'd want to commit any capital at this time given there seem to be some substantial risks.   Are young investors taking too much risk? A comparison of Gen Z, who were born between 1997 through 2012, versus baby boomers, who born from 1946 to 1964, show that Gen Z is taking on much more risk compared to when baby boomers were their age. In a study from the FINRA Investor Education Foundation, 36% of respondents between the ages of 18 to 34 had traded options. This compares to 8% of investors who were 55 years and older. Also revealed in the survey was younger and new investors were more likely to use margin when investing. This came at a surprisingly high rate with 23% of investors between the ages of 18 and 34 saying they had used margin when investing. This compares to just 3% of respondents age 55 and older. What was also interesting and informative is the lack of investing experience as 19% of investors with less than two years of investing experience stated they had used margin. However, just 6% of investors with experience of 10 years or more have used margin. I think many of these older investors are more cautious because they had learned their lesson. There's no doubt that the younger investor today is taking on more risk than the more experienced investors. I believe this is for two reasons. First off, the access to trade and invest is so easy and it can be done on the phone in your hand at essentially any point in time. Compare that to 25-35 years ago when investors had to go through a broker to trade. The second reason I see is the Great Recession in 2008 was 17 years ago and the young investors today were only 5 to 15 years old and had no interest or care about the economy and the crash of the stock market. Investing successfully long-term involves many years of experience and research and unfortunately, I believe the younger investors will learn by experience that the risk they are taking today will not end well.   Weak consumer sentiment brings down stocks Stocks fell on Friday after the headline consumer sentiment index came in at 64.7, which was down 9.8% from January and below the estimate for 67.8. This reading was also down 15.9% compared to this time last year. I was surprised to see the one-year expectation for inflation came in at 4.3%, which was the highest level since November 2023. The five-year outlook increased substantially to 3.5%, which would be the highest reading since April 1995. It was not a major surprise to see sentiment fall for Democrats and stay unchanged for Republicans, but it did fall for Independents. While I think it is important to look at various economic data, I wouldn't say this survey is overly troubling. This survey comes from the University of Michigan and when I was researching how many people it encompasses, I found it includes at least 600 households and is conducted by phone each month. It is designed to be representative of all US households, excluding Alaska and Hawaii, but with such a small data set compared to total US households as of 2023 at 131.43 million, I must say I question how indicative of all US households it truly is. As I said, I don't want to completely disregard this data point, but given the limited insight I would not be overly concerned. I do believe this shows how fickle the market is at this point and even an inkling of bad news could send stocks lower given the high valuations.     Beware the tax trap of renting out your house If you're moving out of your current house, you may be considering converting your home into a rental property.  This may seem like an attractive way to generate additional income. However, before making this move, it's important to be aware of the tax implications, especially the potential loss of the Section 121 capital gain exclusion.  When you sell a primary residence, you may exclude up to $250,000, or $500,000 for married couples, of capital gains if you owned and used the home as your primary residence for at least two out of the previous five years.  When renting out your home, you still own it, but it is no longer considered your primary residence.  If you decide to sell the property more than three years after beginning to rent it, it no longer qualifies for any capital gain exclusion, resulting in a potentially large tax bill, exceeding $185,000 in some cases.  Not only that, but while renting a property you claim depreciation each year.  This reduces your taxable income while owning a rental, but that accumulated depreciation must be “recaptured”, which means taxed, at ordinary income rates when the property is sold.  This recaptured depreciation tax also cannot be offset by the Section 121 exclusion regardless of the timing of the sale. If you want to rent out your home, make sure you either sell it before losing the exclusion, or be committed to being a real estate investor for the long haul.   Companies Discussed: Intel Corporation(INTC), Illumina Inc.(ILMN), The Kraft Heinz Company(KHC) & Him & Hers Health, Inc. (HIMS)

Buenos días y feliz lunes. Hoy toca dar un repaso a las principales noticias tecnológicas del 3 al 9 de febrero. Temores a una guerra comercial impactan negativamente las acciones de grandes automotrices y tecnológicas en EE.UU. tras los aranceles de Trump. Las nuevas políticas arancelarias de la administración Trump provocan una caída significativa en los mercados, afectando principalmente a los sectores automotriz y tecnológico, mientras crece el temor a una guerra comercial global. Tana recauda 25 millones de dólares para revolucionar la productividad laboral con IA. Una nueva promesa tecnológica ha surgido en el ámbito empresarial: Tana, una startup que combina inteligencia artificial con gestión del conocimiento, ha recaudado 25 millones de dólares para continuar desarrollando su innovadora plataforma. Los Beatles y la Inteligencia Artificial hacen historia en los Grammy. La legendaria banda The Beatles marcó un nuevo hito en la historia de la música al ganar el Grammy a la Mejor Interpretación de Rock con su canción «Now and Then» , una creación que combina la tecnología de inteligencia artificial con el talento eterno de la banda. Deep Research de ChatGPT: creando informes a partir de cientos de fuentes en línea. Dos días después del lanzamiento de o3-mini, la compañía anunció una nueva función llamada Deep Research, una herramienta que promete revolucionar la forma en que realizamos investigaciones en línea. Snowflake negocia la compra de Redpanda, la startup de análisis de datos en tiempo real valorada en 500 millones. El mundo de los datos y el análisis está en constante evolución, y esta semana ha surgido una noticia que podría tener un impacto significativo en el sector. Snowflake, el gigante de las bases de datos en la nube, está en conversaciones avanzadas para adquirir Redpanda, una startup especializada en software de análisis de datos en tiempo real. Apple lanza «Invitaciones», una nueva aplicación para crear invitaciones personalizadas y gestionar eventos. La nueva aplicación de Apple permite a los usuarios diseñar invitaciones personalizadas, gestionar confirmaciones de asistencia y crear álbumes compartidos, integrando funciones como Maps, Weather y Apple Music. China responde con sanciones a Google y otras empresas estadounidenses mientras escalan las tensiones comerciales. Beijing impone aranceles y medidas restrictivas contra empresas como Google, PVH e Illumina, en respuesta a los nuevos impuestos estadounidenses sobre productos chinos. Google refuerza Gemini con nuevos modelos de IA y capacidades de procesamiento avanzado. La compañía lanza Gemini 2.0 Pro Experimental y Gemini 2.0 Flash Thinking para mejorar la competitividad de su IA frente a la creciente amenaza de DeepSeek. Amazon Web Services se enfrenta a una prueba clave tras la desaceleración de Microsoft y Google en la nube. Los resultados financieros de Amazon serán analizados de cerca tras los tropiezos de sus principales rivales en el sector de la computación en la nube, en un contexto de dudas sobre la rentabilidad de las inversiones en inteligencia artificial. Google asegura que las aplicaciones comerciales de computación cuántica estarán listas en cinco años. Hartmut Neven, líder de Google Quantum AI, afirma que la compañía está en camino de lanzar aplicaciones prácticas de computación cuántica para 2029, desafiando las predicciones más conservadoras de la industria. Tinder apuesta por la inteligencia artificial para recuperar usuarios y mejorar las coincidencias. Tinder busca una solución innovadora para frenar la disminución de usuarios activos en su plataforma. La aplicación de citas, propiedad de Match Group, ha anunciado que en el próximo trimestre incorporará nuevas funciones impulsadas por inteligencia artificial (IA) con el objetivo de mejorar la experiencia de los usuarios y ofrecer coincidencias más personalizadas y relevantes. Stellantis amplía su alianza con Mistral AI para acelerar el análisis de datos en la industria automotriz. El fabricante de automóviles Stellantis refuerza su asociación con la firma francesa de inteligencia artificial para optimizar el desarrollo de productos y la toma de decisiones empresariales. Apple prepara el lanzamiento del nuevo iPhone SE: llegaría la próxima semana con diseño renovado y USB-C. Según Bloomberg, Apple anunciará su próximo iPhone SE en los próximos días, con un diseño actualizado, puerto USB-C y posibles novedades como Face ID y el procesador A18. Por qué ByteDance podría permitirse cerrar el negocio estadounidense de TikTok. La empresa china se enfrenta a la obligación de vender TikTok en EE. UU. antes del 19 de enero de 2025 o afrontar su prohibición total. Sin embargo, ByteDance considera que cerrar la plataforma es una mejor alternativa a una venta forzada. El Reino Unido ordena a Apple crear una «puerta trasera» para acceder a copias de seguridad cifradas de iCloud a nivel mundial. Una orden secreta basada en la Ley de Poderes de Investigación del Reino Unido exige a Apple permitir el acceso de las autoridades británicas a las copias de seguridad cifradas de iCloud, incluyendo las de usuarios fuera del país. Netflix cancela el polémico documental sobre Prince tras disputas con sus herederos. Los herederos del icónico músico llegarán a un acuerdo con Netflix para desarrollar un nuevo proyecto, tras criticar el enfoque "sensacionalista" y las inexactitudes del documental original.

El mercado sigue muy de cerca las cotizaciones de Amazon, Microchip Technology, Walgreens, Illumina, Tesla y el gigante del streaming Netflix. Con Rafael Ojeda, analista independiente.

“There’s no digital feedback loop in health care, you have it in Tesla, in Netflix, in Amazon — but not in the industry that impacts every life,” Terry Myerson, CEO of Truveta, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Myerson joins BI analyst Jonathan Palmer to discuss Truveta’s mission to aggregate and analyze health data across 30 major US health systems, covering one-third of Americans. He details the company’s work in regulatory-grade safety and efficacy research, the launch of the Truveta Genome Project with partners like Regeneron and Illumina, and the power of AI-driven insights to accelerate medical discovery. The conversation explores Truveta’s efforts to address data fragmentation, privacy, and interoperability challenges that must be solved to revolutionize patient care and life sciences.See omnystudio.com/listener for privacy information.

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking new research using its Parsortix system. The study, conducted by the Marchetti lab at the University of New Mexico Comprehensive Cancer Center, uncovered key insights into how cancer spreads. Newland explained that Parsortix, the only FDA-cleared system for recovering cancer cells for analysis, was used to study circulating tumor cell (CTC) clusters. The research found that B cells influence the movement of cancer clusters, accelerating metastasis. These findings open new avenues for understanding and potentially preventing cancer spread. The study also suggests that detecting B cell CTC clusters in melanoma patients could help identify those at risk of disease progression. Pharmaceutical companies may explore ways to target these mechanisms to slow or stop metastasis. Additionally, Newland highlighted a collaboration with Illumina, with ANGLE set to present at an Illumina webinar. This event could drive further adoption of Parsortix for advanced cancer research. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like, subscribe, and enable notifications for future content. #ANGLEPLC #CancerResearch #Parsortix #CTCClusters #Metastasis #Biotech #LiquidBiopsy #Illumina #MedicalBreakthrough #FDAApproved

China will impose tariffs on select U.S. imports in response to U.S. tariffs initiated by President Trump. Starting next week, China will enforce a 15% tariff on coal and liquefied natural gas, alongside a 10% tariff on crude oil, agricultural machinery, and large-engine vehicles. The State Council Tariff Commission criticized U.S. tariffs as violations of World Trade Organization rules. China will also implement export controls on minerals essential for high-tech production, impacting U.S. economic and national security. Simultaneously, China will investigate Google, citing complaints from local manufacturers about Android practices. Two U.S. companies, PVH Group and Illumina, face potential restrictions due to their placement on an unreliable entities list.Learn more on this news visit us at: https://greyjournal.net/ Hosted on Acast. See acast.com/privacy for more information.

In the previous episode we heard how some rationally-designed therapies work on almost any cancer with the right molecular signature. Tumour-agnostic medications could be godsend for patients with rare cancers which have classically been overlooked by drug developers, and those with advanced cancers of unknown origin. 15,000 such patients have undergone comprehensive genome profiling of their tumours through the organisation, Omico. In this podcast, Omico's founder explains that while the majority have received recommendations about matched therapies, clinical trials are typically the only way to enable access. Professor David Thomas discusses why Australia's Health Technology Assessment process appears to be so conservative and how the market price of next-generation oncotherapies might be brought down by changes across the local ecosystem. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico)  Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes  ‘Multicolor' and ‘Pulse Voyage' by Chill Cole. ‘Impulsing', ‘the City of Hope' ‘Over Again', and ‘Going Undercover' by Borrtex provided courtesy of FreeMusicArchive. Image by Guido Mieth licenced through Getty Images.  Editorial feedback kindly provided by RACP physicians Simeon Wong, Stephen Bacchi. Thanks also to Kym Bramich and Arnika Martus on staff with Omico and RACP respectively.  Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

In this episode we speak with Wenqing (Sienna) Zhang (MPH '17), a trailblazer in public health and global healthcare innovation. Sienna shares how her passion for medical technology led her from studying pharmaceutical sciences to pursuing a master's in biostatistics and epidemiology at NYU. She recounts pivotal experiences, including internships at Pfizer and the NYC Department of Health, her role at Medtronic's first innovation accelerator in China, and her current work at Illumina, where she is driving advancements in gene sequencing worldwide. A Forbes 30 Under 30 honoree, Sienna offers candid insights into her cross-cultural career, her strategies for connecting innovation with business, and how she overcame challenges to lead in multinational settings. To learn more about the NYU School of Global Public Health, and how our innovative programs are training the next generation of public health leaders, visit http://www.publichealth.nyu.edu.

The genomic understanding of cancer has transformed a tissue-based classification model that had been dominant for 150 years or more. The last three decades have seen highly targeted therapies developed at blistering pace, and unprecedented improvements in patient outcomes. To date, these advances have been focused on more common cancers. The financing model for drug development means that rare cancers get overlooked, given the small pool of potential buyers relative to the costs and risks of investment. However, the molecular targets characterised in more common cancers are often found in cancers of a different histotype. As such, precision therapies will sometimes have tissue-agnostic efficacy and offer a lifeline for patients with neglected diseases or cancers of unknown origin. Professor David Thomas has founded an NGO called Omico to enable such patients to undergo profiling for hundreds of potential molecular targets. In this interview he explains the rationale for the most promising pan cancer therapies, and in the next episode we discuss changes to the regulatory and funding model required to sustain this screening program. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico) Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘the Orchard' by Jakob Ahlbom, ‘Dusty Electronics' and ‘Pulse Voyage' by Chill Cole, ‘Tam' by LJ Kruzer, ‘See you soon' and ‘Going Undercover' by Borrtex. Image by filo licenced through Getty Images. Editorial feedback was kindly provided by RACP physicians Nichola Ball, Stephen Bacchi, Aafreen Khalid, Simeon Wong, Maansi Arora and Aidan Tan.Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

DNA methylation, a cornerstone of epigenetic research, is vital for understanding gene regulation and its implications in health and disease. In this week's episode of the Everything Epigenetics podcast, I speak with David Goldberg and Nicole Renke about the latest advancements in DNA methylation tools, including Illumina's groundbreaking Methylation Screening Array (MSA).We explore the history and evolution of methylation microarrays, why they remain the gold standard for Epigenome-Wide Association Studies (EWAS), and the design process behind the MSA array. David and Nicole provide insight into the practical applications of these tools for research in aging, neurodegenerative disorders, and environmental exposures.You'll learn about:•⁠  ⁠What methylation microarrays are and why they're essential for EWAS•⁠  ⁠The market need and vision for Illumina's new MSA array•⁠  ⁠Key features and benefits of the MSA array for researchers•⁠  ⁠The role of cell-specific methylation in advancing epigenetic studies•⁠  ⁠Insights into the technical and biological validation of the MSA arrayChapters:00:00 Welcome and Introduction02:30 History of Methylation Microarrays10:45 Applications of EWAS in Research20:15 Unveiling the MSA Array: Vision and Design35:00 Technical Validation and Biological Insights45:30 Future Directions in DNA Methylation Research50:00 Closing RemarksSupport the showWhere to Find Us:Instagram Twitter Facebook Follow us on:Apple Podcast Spotify YouTube Visit our website for more information and resources: everythingepigenetics.com Thank you for joining us at the Everything Epigenetics Podcast and remember you have control over your Epigenetics, so tune in next time to learn more about how to harness this knowledge for your benefit.

Imagine a future where healthcare isn't just reactive but deeply personalized — where every patient gets the right treatment at the right time based on a precise understanding of their biology. This is the future Ovation is building, and on this week's Founded & Funded, Madrona Partner Chris Picardo dives into it all with Ovation CEO Curt Medeiros. From transforming underutilized clinical data into rich multiomics datasets to forging industry-leading partnerships with companies like Illumina, Curt shares how Ovation is shaping the future of precision medicine. He also opens up about the challenges of building a scalable, privacy-first platform, the lessons he's brought from leading large healthcare businesses, and why collaboration and diversity are key to solving complex problems in healthcare. Transcript: https://www.madrona.com/curt-medeiros-on-revolutionizing-precision-medicine-and-scaling-ovation Chapters: (00:00) Introduction (01:32) Ovation's Role in Precision Medicine(03:17) The Importance of Data in Precision Medicine(06:12) Challenges and Opportunities of Genomic Data (11:17) Privacy and Pharmaceutical Applications (16:42) Ovation's Unique Approach and Partnerships (17:00) Expanding Research Beyond Pharma(18:28) Recent Successes and Future Plans(26:36) Curt Medeiros' Journey to Ovation(29:56) Leadership Philosophy and Company Culture(33:21) Future of Precision Medicine

933: Through advanced data and AI, healthcare companies are transforming care with precision health, delivering earlier diagnoses and personalized treatments. At Illumina, CIO Carissa Rollins is leading the charge, modernizing the tech stack to power the future of precision health. In this episode of Technovation, Carissa discusses how technology is reshaping genomics, sharing her efforts to streamline IT, foster AI innovation, and tackle global challenges like cancer and rare diseases. Host Peter High explores Carissa's journey to becoming a CIO, her leadership in change management, and her vision for advancing precision health.

In today's episode of The Root Cause Medicine Podcast, Brian Maurer, Co-Founder of Bristle Health, joins Dr. Kate Kresge to dive into the Rupa Health and Bristle Health partnership to change the game in oral microbiome testing. You'll hear us discuss: 1. How Bristle Health is transforming oral microbiome testing 2. How oral bacteria impact your whole body 3. Why brushing and flossing isn't enough to beat cavities 4. The link between oral health and autoimmune diseases Over seven years, Brian played a key role in driving the adoption of genomics at companies like Illumina, focusing on expanding their reach into new and emerging markets. At Twist Bioscience, he managed the growth of their genomic sequencing business in Northern California. Passionate about healthcare innovation, Brian is dedicated to leveraging cutting-edge technology to improve patient outcomes. Order tests through Rupa Health, the BEST place to order functional medicine lab tests from 30+ labs - https://www.rupahealth.com/reference-guide

Víctor Galán, analista de Planeta Bolsa, examina los títulos de Zalando, Amazon, IAG, Deutsche Bank, Apple, Elli lilly o Illumina, entre otros

In this episode I explain what the arrival fallacy is, how it could be holding you back from finding peace, and how to break free from this fallacy!To listen to the full episode (plus hundreds more webinars and resources to help you live your happiest life) AD-FREE download the Neurocycle app here: https://www.neurocycle.app/Sponsors making this show possible:-IRESTORE: So treat yourself to some high-tech self-care with iRestore's Illumina face mask. For a limited time only, our listeners get 25% off their Illumina Face Mask when you use code DRLEAF25 at https://iRestorelaser.com

Welcome to the Rose Woman Podcast, where we explore the cutting edge of health, wellness, and personal empowerment. Today, we have a very special guest - Dr. Michael Snyder, a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project.He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. Dr. Snyder is the cofounder of Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, Protos, Protometrix (now part of Thermo-Fisher). Affomix (now part of Illumina).This is an episode that just might change the way you think about your health and the future of healthcare - don't miss it.In this episode, we cover:Importance of measuring health frequently while people are still healthy to detect early signs of diseaseThe use of wearables, such as smartwatches and Oura rings, plays a crucial role in early detectionBreakdown of omics concepts like genomics, proteomics, and metabolomicsThe role of hormones in aging and the impact of andropause and menopauseEmphasis on the importance of exercise and strength training for overall healthAdvancements in DNA sequencing, mass spectrometry, and wearablesThe importance of continuous data collection and the role of AI in integrating and analyzing large datasetsThe challenges of implementing proactive health monitoring in the current healthcare systemImportance of financial incentives and the role of employers in promoting health and wellnessVision for the future of healthcare with continuous health monitoring and AI-powered personalized recommendationsThe role of hormones and agingHelpful links:Michael Snyder, Ph.D. - Stanford W. Ascherman Professor of Genetics and SnyderlabGenomics and Personalized Medicine: What Everyone Needs to KnowFounder Letter: The New Science on Aging Well by Christine MasonFind Rosebud Woman on Instagram as @rosebudwoman, Christine on Instagram as @christinemariemasonFind Radiant Farms on Instagram @weareradiantfarms Hosted on Acast. See acast.com/privacy for more information.

Welcome to the latest episode of the FocusCore podcast. In this episode we are talking about the field of Genomics and how the applied genomics technology company, Illumina is pushing the boundaries of genomic biotechnology for research and in applied medicine. Our guest is General Manager and Representative Director of Illumina KK, Arjuna Kumarasuriyar. Arjuna has commercial experience in sales, marketing, channel management and commercial operations, as well as an academic background in biotechnology and molecular biology. In the episode we dive deep into what genomics is and how it is evolving, as well as hearing some of Arjuna's insights into Japan's unique business landscape.In this episode you will hear:What the term genomics means and how it differs from geneticsWhat made Arjuna change his study from medicine to biotechnologyAbout Illumina's work in biotechnologyHow the technology Illumina is developing is fundamentally changing healthcare around the worldWhat Arjuna has learnt about doing business in JapanHow AI technology might impact genomicsAbout Arjuna Kumarasuriyar:Arjuna Kumarasuriyar has Commercial experience in sales, marketing, channel management and Commercial Operations in the life sciences sector. The majority of Arjuna's career has been in genomics with Illumina covering business across the Asia Pacific region. The first eight years of his career at Illumina were in sales, marketing and sales management roles. The next eight years he established and grew a commercial operations function to support the rapidly expanding commercial team in Asia through analytics, processes, technology, training and back office functions. Arjuna has been General Manager and Representative Director of Illumina KK since January 2023. He is passionate about finding ways for teams to perform at their best whether it is shaping organizational structures and culture or getting into the operational enablement to enable efficient and effective customer value creation.Arjuna has a Bachelors in Biotechnology and a PhD in Molecular Biology from the University of Queensland, Australia. He joined Illumina in 2007 after working in R&D, quality assurance, and technology transfer roles for several biotech companies and government agencies in Singapore and Australia. Connect with Arjuna Kumarasuriyar:LinkedIn: https://www.linkedin.com/in/arjunakumarasuriyar/X: https://x.com/ArjunaKConnect with David Sweet:LinkedIn: https://www.linkedin.com/in/drdavidsweet/ Twitter: https://twitter.com/focuscorejp Facebook: :https://www.facebook.com/focuscoreasiaInstagram: https://www.instagram.com/focuscorejp/ Website: https://www.japan.focuscoregroup.com/ “Doin' the Uptown Lowdown,” used by permission of Christopher Davis-Shannon. To find out more, check out www.thetinman.co. Support independent musicians and artists.

Veteran analyst Edward Schneider explains his investment philosophy for extremely fundamentally overvalued shorts (1:10). Timing the semiconductor cycle (5:15). Value investing in tech is challenging; go for reasonable growth stocks (8:50). Setting a fair value for Illumina (17:20). This was recorded on November 4.Show Notes:Revisiting IlluminaNWTN Inc.: The Perfect Fundamental ShortCuriosityStream: Too Cheap To IgnoreRead the transcriptFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Dr. Jonathon Hill, VP of Science and Technology and Co-Founder of Wasatch Bio Labs has developed the Next-Generation Sequencing 3.0, NESSI-Seq platform, which can analyze blood to detect epigenetic changes and provide insights into current health and predisposition for diseases. This native-read third-generation sequencing tool can provide longer sequence reads and analyze epigenetic modifications to DNA. Epigenetics can change over time in response to diet, environment, and lifestyle. Advanced genetic testing has the potential to provide biomarkers to support personalized medicine for earlier detection and tailored interventions. Jonathon explains, "The biggest limitation with the Illumina sequencing was that it was only short sequences, so you had to get a lot of them to stitch them together and figure out what the human genome looked like. With this third-generation sequencing, we can get much longer reads, sometimes to the order of a hundred thousand nucleotide bases at a time. So we get these big complex reads." "The other thing we can do now with this third-generation sequencing is look at certain chemical modifications the body makes to the DNA to help regulate that DNA and help the body function. And looking at those chemical modifications can tell us a lot about someone's health. It can tell us their age, and it can tell us what disease they might have. We can get a lot of information out of that that just wasn't available to us in the previous two generations."  "If you think of classical genetics, it's the DNA sequence and the mutations you might have that might give you a propensity for the disease, etc. Those don't change throughout your life. Every cell in your body has that exact same sequence from birth until death. It never changes. But the epigenetics, these chemical modifications change. They change as you age. They are different in different tissues and organs within your body, changing even in response to pathogens or certain disease states. So they have a lot of information that we would not get otherwise." #WasatchBioLabs #Epigenetics #GeneticResearch #PersonalizedMedicine #DNAInnovation #GeneticTesting #NextGenSequencing #BiotechBreakthroughs #GeneRegulation #HealthcareInnovation #FutureofMedicine Wasatchbiolabs.com Download the transcript here

Dr. Jonathon Hill, VP of Science and Technology and Co-Founder of Wasatch Bio Labs has developed the Next-Generation Sequencing 3.0, NESSI-Seq platform, which can analyze blood to detect epigenetic changes and provide insights into current health and predisposition for diseases. This native-read third-generation sequencing tool can provide longer sequence reads and analyze epigenetic modifications to DNA. Epigenetics can change over time in response to diet, environment, and lifestyle. Advanced genetic testing has the potential to provide biomarkers to support personalized medicine for earlier detection and tailored interventions. Jonathon explains, "The biggest limitation with the Illumina sequencing was that it was only short sequences, so you had to get a lot of them to stitch them together and figure out what the human genome looked like. With this third-generation sequencing, we can get much longer reads, sometimes to the order of a hundred thousand nucleotide bases at a time. So we get these big complex reads." "The other thing we can do now with this third-generation sequencing is look at certain chemical modifications the body makes to the DNA to help regulate that DNA and help the body function. And looking at those chemical modifications can tell us a lot about someone's health. It can tell us their age, and it can tell us what disease they might have. We can get a lot of information out of that that just wasn't available to us in the previous two generations."  "If you think of classical genetics, it's the DNA sequence and the mutations you might have that might give you a propensity for the disease, etc. Those don't change throughout your life. Every cell in your body has that exact same sequence from birth until death. It never changes. But the epigenetics, these chemical modifications change. They change as you age. They are different in different tissues and organs within your body, changing even in response to pathogens or certain disease states. So they have a lot of information that we would not get otherwise." #WasatchBioLabs #Epigenetics #GeneticResearch #PersonalizedMedicine #DNAInnovation #GeneticTesting #NextGenSequencing #BiotechBreakthroughs #GeneRegulation #HealthcareInnovation #FutureofMedicine Wasatchbiolabs.com Listen to the podcast here

In this episode I interview Richard C Schwartz, the creator of Internal Family Systems (IFS). IFS is a highly effective, evidence-based therapeutic model that de-pathologizes the multipart personality. We discuss:How he came to develop this system and how it is helping millions around the world How the mind is naturally multiple and that is a good thing.How IFS creates inner and outer connectedness by helping people first access their Self and, from that core, come to understand and heal their parts. How It is also a way of understanding personal and intimate relationships and stepping into life with the 8 Cs: confidence, calm, compassion, courage, creativity, clarity, curiosity, and connectedness.Learn more about IFS here: https://ifs-institute.com/Sponsors making this show possible:-Fatty15: Fatty15 is on a mission to replenish your C15 levels and restore your long-term health! You can now get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DRLEAF and using code DRLEAF at checkout for an additional 15% off your first order! -IRESTORE: So treat yourself to some high-tech self-care with iRestore's Illumina face mask. For a limited time only, our listeners get 25% off their Illumina Face Mask when you use code DRLEAF25 at https://iRestorelaser.com

In this episode I chat with Neurocycle Facilitator Christie O'Brien about:Identifying the root of body image issues and eating disorders How to find sustainable heal thing using the Neurocycle method How to rewire your brain in 63 days To work with Christy visit: https://www.christieobrien.com/neurocycle.htmlGet the Neurocycle app here: https://www.neurocycle.app/Sponsors making this show possible:-Purity Woods: Honestly, I have never seen a skincare product of this quality at this reasonable of a price point. And thankfully, the good people at Purity Woods have a special coupon code specifically for my listeners, so you can try it for yourself for 27% off today. Just go to puritywoods.com/MENTALMESS or enter MENTALMESS at checkout.-IRESTORE: So treat yourself to some high-tech self-care with iRestore's Illumina face mask. For a limited time only, our listeners get 25% off their Illumina Face Mask when you use code DRLEAF25 at irestorelaser.com

Dive headfirst into the strangest and spookiest encounters yet—from hooded figures to cursed classmates and even a town that might not exist! From cryptids and curses to alien encounters, this episode is full of strange, creepy, and downright spine-tingling stories. You won't want to miss it! Episode Highlights:

In this episode, Bryan Roberts, a partner at Venrock and one of the healthcare industry's most illustrious investors, shares insights from his 25+ year career. We cover:The traits that have contributed to his success in healthcare investingHow to navigate investment cycles and make non-consensus decisionsBryan's early investments in Illumina and Athena HealthThe current state of digital health and value-based careThe potential impact of AI on healthcare efficiency and clinical practiceExits and IPOs in the current marketLessons from Bryan's biggest missesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The European Commission's attempt to claim jurisdiction under the EU merger rules over Illumina's acquisition of GRAIL ultimately resulted in a stinging court defeat for the regulator. But why did it lose and what will happen now to merger reviews of "below threshold" transactions in the EU? Nicole Kar, partner at Paul, Weiss in London, joins Matthew Hall and James Hunsberger to discuss the Commission's 2021 re-interpretation of its powers under Article 22 of the EU Merger Regulation, the European Court of Justice judgment striking that down and the alternative avenues for the Commission or EU countries to claim jurisdiction over killer and reverse killer transactions. Listen to this episode to learn more about how to analyse the risk and practical steps to take in relation to these transactions. With special guest: Nicole Kar, Partner, Paul, Weiss, Rifkind, Wharton & Garrison LLP Related Links: European Commission March 2021 guidance on use of Article 22 of the EU Merger Regulation European Commission FAQ on March 2021 Article 22 guidance General Court judgment 13 July 2022 on application of Article 22 by European Commission in Illumina/GRAIL Advocate General opinion 21 March 2024 on application of Article 22 by European Commission in Illumina/GRAIL European Court of Justice judgment 3 September 2024 on application of Article 22 by European Commission in Illumina/GRAIL Paul, Weiss, Rifkind, Wharton & Garrison LLP Client Memorandum "Mind the Gap: ECJ Judgment Determines European Commission Cannot Review Deals Below Member State Merger Control Thresholds" Hosted by: James Hunsberger, Axinn, Veltrop & Harkrider LLP and Matthew Hall, McGuireWoods London LLP

In this episode of Naked Genetics: How much of your personality is down to your DNA; we also look at synthetic DNA, and why we'd want to make it; plus, the spiders that turn one species of insect against its own kind... Like this podcast? Please help us by supporting the Naked Scientists

本集節目由【動態特效網頁設計全攻略】贊助 就算不是接到業配合作，我也會想跟大家推薦這堂課程。 一直覺得做個好網頁很重要，但卻總是掌握不到訣竅。後來發現真正的問題是我根本不具備一個系統性的概念，包括：視覺動線、基本的美感、什麼叫動態，以及怎麼部署動態。詳細資訊推薦大家到下方網站上看更完整的介紹，我自己也會上這堂。 ✨0 基礎、0 程式也可以做出動態網頁！升級個人職場硬技能✨ ◼️ 大師親自教學｜全台動態網頁先驅親自傳授 10 年網站設計經驗 ◼️ 即學即用｜新手也能無痛跟練做出七大作品，馬上應用！ ◼️ 網頁成效提升｜學會應用超過 10 組的動態特效，網頁吸睛度加倍！ ◼️ 職能價值翻倍｜跟上最新網站趨勢，大幅提升自我技能、接案價碼再翻倍！ ◼️ 獨家心法大公開｜獨家 400 組吸睛網頁 #設計心法 不藏私

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Chinas Konjunkturpaket, Donald Trumps Attacke auf die deutschen Autobauer und die Monopolklage gegen Visa. Außerdem geht es um Nvidia, Estée Lauder, LVMH, Kering BMW, Volkswagen, Mercedes, Porsche, Commerzbank, Mastercard, Alibaba, JD.com, BYD, NIO, ishares Core S&P 500 ETF (WKN: A0YEDG), SPDR S&P U.S. Utilities Select Sector ETF (WKN: A14QB6), NextEra Energy, The Southern, L&G E-Commerce Logistics ETF (WKN: A2H5GL), Walmart, Alibaba, eBay, DHL, Kühne&Nagel, DSV, FedEx, Duke Energy, Constellation Energy, L&G Russell 2000 US Small Cap Quality ETF (WKN: A0Q8H2), Hamilton Lane, Hims&Hers Health, Abercrombie&Fitch, HAN-GINS Tech Megatrend ETF (WKN: A2JR0J), TeraWulf, Snap, Grindr, Nvidia, Dell, Invesco NASDAQ Biotech ETF (WKN: A12CCJ), Vertex, Moderna, Biomarin, Illumina, EUWAX Gold II ETC (WKN: EWG2LD) und iShares Core MSCI EM IMI ETF (WKN: A2JDYF). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In the latest instalment of Cleary Gottlieb's Antitrust Review podcast, host Nick Levy is joined by the team of lawyers who represented Illumina in its landmark appeal to the European Court of Justice, which last week overturned the Commission's assertion of jurisdiction under the EU Merger Regulation over below-threshold mergers. Mario Siragusa, Enrique González-Díaz, Cesare Rizza, and Anita Magraner Oliver explain how they litigated the case, why the Court of Justice sided with Illumina, and what implications the Court's judgment will have for EU merger control.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Viral vector manufacturers are facing challenges such as high production expenses, low titers, empty capsids, and limited scalability when producing cell and gene therapies. To overcome these challenges, they are turning to next generation production processes to create a cost-effective and robust AAV manufacturing process. This new approach aims to produce higher titers and full capsids, increase efficiencies resulting from high yields, and drive down the cost per dose. By implementing these strategies, manufacturers can improve the productivity of AAV production and bring promising treatments to the market more effectively.Embecta received FDA approval for its insulin patch pump, featuring a larger insulin reservoir based on feedback from people with type 2 diabetes. Meanwhile, Illumina avoided a fine for its acquisition of Grail in a European court victory. The ARPA-H program will focus on AI degradation in medical tools, while a pathology group is suing to block an FDA lab test rule. Additionally, Medtronic's chief medical officer of acute care and monitoring has departed for a new role.The text discusses various updates in the biopharma industry as of September 3, 2024. It covers topics such as the next challenger to Prevner, advancements in AI drug discovery, concerns over suicide risk of obesity drugs, Recursion's lead drug safety, Vaxcyte's positive data for a pneumococcal vaccine, Sanofi's mixed results in MS drug trials, and the value of digital insights in pharma success.A new study predicts a healthcare labor shortage by 2028, with certain states and specialties facing acute shortages. The study also reveals disparities in fighting medical bills, as uninsured and less educated patients are less likely to question their bills. The ARPA-H program will focus on addressing AI degradation in medical tools. Other updates include tracking healthcare worker strikes and data breaches. The use of technology is transforming healthcare to combat challenges such as workforce shortages and shifting care utilization patterns.FDA Commissioner Dr. Robert Califf is considering reforms to advisory committees, including potentially scrapping expert voting in some circumstances. Califf believes that the discussions within these committees may be more valuable to the FDA than the final vote outcomes. Eliminating voting could help clarify the role of advisory committees. Other potential reforms being discussed include addressing conflicts of interest.The text discusses the importance of getting the Institutional Review Board (IRB) review right the first time and introduces a checklist of critical questions to ask potential IRB partners to ensure a smoother review process. By asking the right questions and choosing the right IRB, the review process can be more efficient and effective.Novo Nordisk's drug Ozempic will continue to face shortages into the fourth quarter due to supply issues, even as the company tries to expand its indication. Astellas Gene Therapies is closing its biomanufacturing facility in San Francisco, affecting about 100 employees and shifting manufacturing to North Carolina.In a landscape where consumers are willing to switch brands to save money, it is crucial for brands to establish and maintain loyalty among shoppers. By leading with value, moving consumers from awareness to loyalty to advocacy, and creating connection and community, brands can build brand love even in the face of economic pressures.The text discusses how emerging oncology innovations have led to more effective therapies for cancer patients. The increased investment in cancer research has introduced new treatments such as cell and gene therapies, antibody drug conjugates, and checkpoint inhibitors. Despite these advancements, the industry still faces challenges in expanding access and improving outcomes.

Plus: Two Russian ballistic missiles hit a military institute and a hospital in central Ukraine. The European Court of Justice said the EU's competition authority lacked jurisdiction when it reviewed U.S. gene-sequencing company Illumina's takeover of cancer-test maker Grail. J.R. Whalen reports. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — FDA approves Illumina cancer biomarker test  The bad — BioMarin reveals more layoffs  The ugly — FDA hits API maker Global Calcium with 483 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Clinical trials often fail to meet their enrollment goals and schedules, leading to significant financial losses. A new playbook offers solutions to address common challenges in clinical trial recruitment, including strategies for identifying additional participants, engaging and empowering individuals, and refining protocol criteria. The playbook provides insights on how to rescue trials when misalignment occurs, aiming to help brands in the biopharma industry tell compelling stories, build trust, and drive demand.Penumbra has decided to exit the virtual reality business, resulting in the layoff of 71 employees, as the company shifts its focus back to its core thrombectomy business. Qiagen and AstraZeneca have expanded their companion diagnostic partnership beyond cancer, allowing specialty care providers to perform genotyping during routine clinical examinations. Illumina has received FDA approval for a companion diagnostic cancer test that can identify patients eligible for treatment with specific medications targeting genetic features. Johns Hopkins, CareFirst, and Techstars have launched a healthcare AI accelerator program to support up to 12 startups working on AI tools. Medical sales teams are increasingly investing in training and skills development to adopt a more human-centered approach to sales.Biopharmaceutical company BioMarin has announced its second round of layoffs this year, with 225 employees globally being let go. This comes after changes to the company's C-suite last week and a previous round of 170 job cuts in May. In other news, Novartis is expanding its Sirna therapy Leqvio after successful Phase III study results, while Merck has ended two late-stage studies of Keytruda due to disappointing data. Regeneron is suing Sandoz in federal court to block a biosimilar of its drug Eylea. The pharma industry continues to see changes and challenges, with companies making strategic decisions based on clinical trial results and market conditions.Cognition Therapeutics, a small biotech company, recently announced positive results from a mid-stage Alzheimer's study. However, despite the promising results, the company's share price plummeted, puzzling many. The conflicting narratives surrounding the study highlight the significance of presenting scientific results in a way that reassures investors about the risks involved. The success of clinical trials is crucial for small biotechs in the competitive field of Alzheimer's research. Investor support is essential for advancing treatments for Alzheimer's, as progress cannot be made without adequate funding.The Health and Human Services (HHS) plans to appeal a lawsuit decision regarding online tracking technology. The Northwell-Nuvance merger has been approved by state attorneys general with certain conditions, while McLaren Health Care has restored its network after a ransomware attack. The shortage of mental health providers is being addressed with digital tools, and efforts to combat burnout in healthcare are ongoing.Neurocrine's mixed schizophrenia data disappoint Wall Street despite "positive" results, leading to a 20% slide in shares. The FDA rejection of the first MDMA therapy signals challenges in the psychedelic drug field. Bayer partners with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. A study suggests that covering Wegovy for heart risk could cost Medicare tens of billions each year.Pfizer has partnered with Flagship's Quotient to utilize genetics in targeting heart and kidney diseases. Moderna is facing tough competition as it tries to determine its next move in the biopharmaceutical industry. Neurocrine Biosciences saw a drop in shares despite meeting the primary endpoint in a mid-stage schizophrenia trial.Lykos Therapeutics faced a setback when the FDA rejected its MDMA therapy for PTSD and laun

In this episode of Naked Genetics: A mammoth discovery in ancient DNA structure; on the subject of ancient DNA, what can we sequence for a centuries old body? And, in quirks of evolution, the animal that drinks its own offspring's blood... Like this podcast? Please help us by supporting the Naked Scientists

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The FDA recently approved Ascendis' drug for a rare endocrine condition, while rejecting MDMA as a therapy aid for PTSD. Pfizer also presented data supporting a case for an RSV shot for immunocompromised adults. Zepbound shortages are starting to ease, but Lilly warns of potential pharmacy availability issues. Galderma has received FDA approval for a skin condition treatment, Nemluvio. In the biotech industry, trends in emerging technologies like gene editing, messenger RNA, and cell therapies are promising new types of medicines. Additionally, there is ongoing progress in cell therapy's impact on cancer care. Despite Merck's TIGIT drug failing another trial, Intellia's therapy succeeded in an HAE study.In other news, Grail plans to cut 350 employees as part of a restructuring effort, while Otsuka Precision Health launches the first digital therapeutic for depression. Globus receives a warning letter over its spine navigation robot, Baxter agrees to sell its kidney care unit to Carlyle for $3.8 billion, and Medtronic wins FDA approval for asleep deep brain stimulation surgery. The medical technology industry is also seeing updates such as FDA approvals for telemonitoring connectivity devices and concerns about undetected bird flu cases.Evotec and Grail have announced job cuts, with Evotec exiting gene therapy and Grail shedding 350 workers. Acelyrin is pivoting away from its main drug and laying off staff to focus on a treatment for thyroid eye disease. Pfizer has appointed an AI chief to expand its digital leadership team. Lilly has opened an R&D hub, while Ovid and Lexicon have laid off staff. The biopharma industry is shifting towards more patient-centric commercialization strategies.Grail is planning to reduce its current workforce by 25% in order to focus on multi-cancer diagnostics. Illumina has outlined a growth roadmap after divesting from Grail, focusing on easier DNA sequencing and improved data analysis for customers. Additionally, companies like Pfizer and Biontech are now shifting their focus to oncology drugs after finding success with COVID-19 vaccines.Experts are analyzing the potential impact of the Inflation Reduction Act (IRA) as the industry awaits the first negotiated drug prices under Medicare. The biotech industry is adapting to a new normal, with M&A activity surging and IPOs making a return. Companies like Lilly and Boundless Bio are making moves in R&D and workforce adjustments.Overall, the biotech industry is navigating a changing business landscape marked by strategic consolidation and renewed investor focus on innovation.Support the Show.

Today's guest is Brenda Kahl, Senior Director of Service and Support at Illumina. Illumina is a San Diego-based biotechnology company founded in 1998 that develops and markets systems for genetic analysis, serving sequencing, genotyping, gene expression, and proteomics markets in over 155 countries. Brenda joins us on today's program to pull apart training challenges for field service operations in biotech spaces and the technology infrastructure necessary to build solutions. Throughout the episode, Brenda gives actionable insights for driving efficiency and cost savings with call center metrics and digital tools, such as tribal knowledge systems that can accommodate new working styles like remote work. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

In this episode we look beyond the UK with guest Huiming Chen discussing the challenges and opportunities of leading finance teams across diverse geographies and cultures with host David McClelland. In her current role as Europe Commercial CFO at Illumina, Huming shares her expertise on acknowledging and bridging cultural differences, fostering open communication, and balancing structural preferences to enhance team performance. Hear her secret to effectively navigating cultural nuances and improve collaboration within a global finance team. Gain a deeper understanding of the intricacies of feedback and communication styles in multicultural environments through Huiming's personal journey from China to the US. We also explore the stark contrasts between Eastern and Western feedback approaches and the critical importance of timely, constructive feedback. Hear how small talk, such as the British habit of discussing the weather, plays a significant role in building professional relationships and how to adapt communication styles to fit different cultural contexts. Huiming also provides insight on the future of finance and the evolving role of CFOs in the face of technological advancements. Emphasising the essential traits of successful CFOs and the importance of creating environments where diversity and innovation thrive, Huiming shares strategies to empower finance teams for innovation, balance operational and strategic responsibilities, and leverage AI technology for informed decision-making, ensuring effective global leadership and cultural adaptation in the workplace Huiming will be judging the Global CFO 100 Awards 2024 by Soldo in partnership with HotTopics. This new award honours CFO's who are driving transformative financial strategies and innovative business practices, shaping the future of finance. Entries close on 31st August 2024, for more information visit https://hottopics.ht/global-cfo-100-awards-nominations.  Chapters: (0:00:00) - Global Cultural Challenges in Finance Leadership (0:10:42) - Cultural Feedback and Relationship Building (0:14:41) - Embracing Diversity in Leadership Roles (0:22:38) - Future Traits of Successful CFOs (0:33:53) - Empowering Future Finance Through Technology About Soldo: Soldo provides company cards connected to a powerful management platform. Employees use Soldo cards to buy what they need for work without being out of pocket or going over budget. Finance teams use Soldo to distribute money instantly, while staying in control of who spends, how much, where, and on what. Thousands of businesses, from small to large corporations including Mercedes-Benz, Sony, and Get Your Guide use Soldo to make their business spending simple and efficient. To find out more or to book a demo, visit Soldo. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Vijay Vaswani, Co-Founder & CEO at Omniscope. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering: How travel expands the mind and enables you to amplify your network The founding story of Omniscope and its mission of using tech to help unlock the immune system AI can read the immune system in HD, helping with clinical trials and predictive candidate selection How you should be thinking about AI for drug discovery and drug development And what the t-shirt he wears at work says on the front... Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.   See you at BPI! M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website Don't miss out and we'll see you in September!

In this episode of Naked Genetics: The risk factors between schizophrenia and substance use disorder have had a fresh genetic examination; I put Illumina to the test and ask, 'what difference does washing our hands really make?' And, the the extraordinary way in which dung beetles use the night sky to orientate themselves... Like this podcast? Please help us by supporting the Naked Scientists

Listen & subscribe on Apple, Google, Spotify, and other platforms. Welcome everyone to the weekly San Diego Tech News by Neal Bloom and Fred Grier from Fresh Brewed Tech. I'm Neal Bloom from Fresh Brewed Tech, the Tacos and Tech Podcast, and Interlock Capital. I'm Fred Grier, journalist and author of The Business of San Diego substack. I wrote about the tech industry for the San Diego Business Journal for two years. I covered the ins-and-outs of the startup world for much of that time, breaking news on IPOs, fundraising rounds, and M&A. Promote the show:  Before we dive in, we wanted to ask our listeners and SD Tech fans to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup Community.   6/27 News A word about Brant Cooper Industrial & Logistics Tech event debriefs Dexcom layoffs Illumina spins off Grail again Unigrid raises $12m in Series A   Biotech fundings Rapport filed for IPO Iambic Therapeutics Raises $153M Series B Bright Peak Therapeutics Raises $90M Series C   Events - For full list - check The Social Coyote SDx eventsSD Founder Hike - 7/12